{"schema_version":"secwatch.filing_event.v1","accession":"0001698530-23-000026","form_type":"8-K","ticker":"XCUR","cik":"0001698530","company_name":"EXICURE, INC.","filed_at":"2023-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.185671+00:00","generated_at":"2026-06-17T15:09:41.823513+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Exicure FY2022 net loss $2.6M, revenue $28.8M non-cash; R&D halted; going concern warning","bullets":["Net loss of $2.6M for FY2022 vs $64.1M loss in 2021; revenue $28.8M from non-cash recognition of deferred revenue after AbbVie and Ipsen terminations.","Cash and equivalents $9.8M at 12/31/22; subsequent private placement raised $5.4M gross ($4.6M net); cash expected into Q4 2023.","Going concern: substantial doubt about ability to continue; need additional financing within next few months.","R&D expense down 60% to $19.8M; company halted all R&D and reduced workforce in September 2022.","CBI USA became majority owner (50.4%) after private placement; board expanded to 6, with only one prior director remaining; controlled company exemption."],"urls":{"canonical":"https://secwatch.observer/filing/0001698530-23-000026","json":"https://secwatch.observer/filing/0001698530-23-000026.json","markdown":"https://secwatch.observer/filing/0001698530-23-000026.md","text":"https://secwatch.observer/filing/0001698530-23-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1698530/000169853023000026/0001698530-23-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1698530/000169853023000026/xcur-20230327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T15:09:41.823513+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9ae19e57836e51005180873c39af511c34e17fbd","claim":"EXICURE, INC. reported the year ended December 31, 2022 results: revenue $28.8 million.","evidence_excerpt":"status of the Company as it explores strategic alternatives and this estimate may prove inaccurate and the Company may expend its limited resources sooner. Revenue : Revenue was $28.8 million for the year ended December 31, 2022, reflecting an increase of $29.3 million from revenue of $(0.5) million for the year ended December 31, 2021. The increase in collaboration","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1698530/000169853023000026/0001698530-23-000026-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$28.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}